New drug cocktail tried against tough pancreatic cancer

NCT ID NCT02985125

Completed Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to find the right dose and see if it could slow tumor growth. The trial was small and early-stage, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (LEE011) and everolimus (Afinitor)
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a very early, small study (only 12 people) with no control group. The combination may not improve outcomes and could cause side effects like mouth sores, lung inflammation, or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.